Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | NCF1 | P14598 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24620325 | 0.82 | POLB (0.58) | ADRA2CKDM4EMAPTGAAPTK2B | |
| SCHEMBL22471227 | 0.82 | ALDH1A1 (0.58) | ADRA2CKDM4EMAPTGAAPTK2B | |
| SCHEMBL30168889 | 0.80 | LGMN (0.53) | KDM4EMAPTGAAMAPK1HTT | |
| SCHEMBL546488 | 0.80 | LGMN (0.53) | KDM4EMAPTGAAMAPK1HTT | |
| SCHEMBL2894409 | 0.80 | ALDH1A1 (0.60) | ADRA2CKDM4EMAPTGAAPTK2B | |
| SCHEMBL22471212 | 0.79 | ALDH1A1 (0.58) | ADRA2CKDM4EMAPTGAAPTK2B | |
| SCHEMBL30464713 | 0.79 | ALDH1A1 (0.58) | ADRA2CKDM4EMAPTGAAPTK2B | |
| SCHEMBL15358684 | 0.78 | MAPT (0.44) | ADRA2CKDM4EMAPTGAAPTK2B | |
| SCHEMBL31172405 | 0.76 | ADRA2C (0.72) | ADRA2CKDM4EMAPTGAAPTK2B | |
| SCHEMBL1509507 | 0.76 | ADRA2C (0.72) | ADRA2CKDM4EMAPTGAAPTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2626354-A1 | Viral polymerase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-1718608-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-8030309-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-7582770-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| EP-1718608-A1 | VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20050222236-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080388-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | ADRA2C 3257/4885KDM4E 2636/4885MAPT 69/4885 |
| US-20050222236-A1 | Viral polymerase inhibitors | POLR2A, POLR1E, RPP30 | ADRA2C 3257/4885KDM4E 2636/4885MAPT 69/4885 |
| US-20110015203-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | ADRA2C 3257/4885KDM4E 2636/4885MAPT 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.